CIT-013 high dose: Clinical Trials

3 trials of CIT-013 high dose, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed, 1 active not recruiting. 2 Phase 2, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 22Active not recruiting 1, Completed 1
Phase 11Completed 1

Follow CIT-013 high dose: new trials by email Literature Review of CIT-013 high dose trials Research Report on CIT-013 high dose

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Trial in Healthy Volunteers to Evaluate 150 mg Subcutaneous CIT-013
CIT-013 high dose, Placebo - Healthy Adult
Phase 1CompletedCitryll BV102026-06-232026-10-21
A Study With CIT-013 in HS Patients
CIT-013 high dose, CIT-013 medium dose, Placebo - Hidradenitis Suppurativa (HS)
Phase 2Active not recruitingCitryll BV1082025-10-312026-10-19
A Study With CIT-013 in RA Patients
CIT-013 low dose, CIT-013 high dose, Placebo - Rheumatoid Arthritis
Phase 2CompletedCitryll BV962025-07-292026-10-19

Conditions studied

Arthritis, Rheumatoid (1)  ·  Hidradenitis Suppurativa (1)

Sponsors

Citryll BV (3)

Countries

Netherlands (3)  ·  Germany (2)  ·  Poland (2)  ·  Spain (2)  ·  Belgium (1)  ·  Canada (1)  ·  United Kingdom (1)

Top investigators

Maarten Kraan (3)